GPT and myositis disease: Grade 3 total bilirubin and alanine aminotransferase elevations occurred in 9 (0.5%) and 2 (0.1%) patients, respectively.[2] Wong et al[3] found no serious adverse events observed with the use of SOF/VEL for real-world chronic hepatitis C genotype 3 cohorts, except for myositis in 1 patient.